Mylan And Lupin Get EU Etanercept Nod
European Commission's Final Decision On Biosimilar Approval Due By May
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.
You may also be interested in...
Lupin Picks Up Canadian Approval For Enbrel Biosimilar
Lupin has celebrated the Canadian approval for its Rymti (etanercept) biosimilar, with all indications matching reference product Enbrel. The product represents the third version of Enbrel approved in Canada.
Mylan And Lupin Prepare To Launch EU Etanercept
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
Mylan Is Only Just Beginning Its Biosimilars Journey
Despite having biosimilars of insulin glargine and etanercept that are expected to launch in the US and Europe respectively midway through this year, a biosimilar bevacizumab candidate filed in both regions, an in-development Botox rival still being considered and several other biosimilars already on the market around the world, Mylan insists that its biosimilars journey is just beginning.